How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Inherited Metabolic Disorders Testing Market
- By Test Type: Enzymatic Assays, Molecular Genetic Testing, Newborn Screening, Metabolite Profiling, Next-Generation Sequencing (NGS)
- By Disorder Type: Amino Acid Metabolism Disorders, Organic Acidurias, Fatty Acid Oxidation Disorders, Lysosomal Storage Disorders, Urea Cycle Disorders
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Newborn Screening Centers, Specialized Genetic Testing Centers, Research Institutes
- By Technology: Mass Spectrometry, Polymerase Chain Reaction (PCR), Chromatography Techniques, Microarray Analysis, Whole Exome Sequencing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Enzymatic Assays leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Inherited Metabolic Disorders Testing Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Disorder Type 5
End User 5
Technology 5
Companies profiled
Thermo Fisher Scientific
Abbott Laboratories
Bio-Rad Laboratories
PerkinElmer
F. Hoffmann-La Roche AG
Agilent Technologies
Illumina Inc.
Genzyme Corporation (Sanofi)
Quest Diagnostics
Eurofins Scientific
Sema4
Invitae Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →PerkinElmer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →F. Hoffmann-La Roche AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Genzyme Corporation (Sanofi)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Quest Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Eurofins Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sema4
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Invitae Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Centogene N.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Myriad Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Becton
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Dickinson and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,503M by 2033 · 9.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzymatic Assays57.2
- Molecular Genetic Testing15.7
- Newborn Screening8.0
- Metabolite Profiling10.9
- Next-Generation Sequencing (NGS)8.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,709M → $3,307M · 8.6%
Europe$1,191M → $2,523M · 9.8%
Asia Pacific$1,088M → $2,193M · 9.2%
Latin America$673.4M → $1,217M · 7.7%
Middle East and Africa$518.0M → $1,030M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.192026
9.212027
9.222028
9.222029
9.242030
9.252031
9.262032
9.272033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific19.9
- Abbott Laboratories24.6
- Bio-Rad Laboratories6.6
- PerkinElmer4.8
- F. Hoffmann-La Roche AG11.4
- Agilent Technologies4.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type29.8%
Disorder Type15.8%
End User30.1%
Technology24.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.2
- Europe24.6
- Asia Pacific21.4
- Latin America11.9
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 95 | 73 | 95 | 74 | 84 | 91 | 85 |
| Abbott Laboratories | 70 | 78 | 86 | 93 | 92 | 70 | 82 |
| Bio-Rad Laboratories | 70 | 68 | 72 | 74 | 79 | 65 | 71 |
| PerkinElmer | 63 | 79 | 77 | 58 | 80 | 75 | 72 |
| F. Hoffmann-La Roche AG | 51 | 51 | 64 | 62 | 70 | 64 | 60 |
| Agilent Technologies | 68 | 66 | 57 | 66 | 64 | 67 | 65 |
| Illumina Inc. | 60 | 46 | 56 | 45 | 49 | 50 | 51 |
| Genzyme Corporation (Sanofi) | 51 | 56 | 58 | 42 | 43 | 47 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Abbott Laboratories
- Bio-Rad Laboratories
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Abbott Laboratories | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Bio-Rad Laboratories | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| PerkinElmer | ◐ | ✓ | ◐ | − | ✓ | ◐ |
| F. Hoffmann-La Roche AG | − | ◐ | ◐ | ◐ | ✓ | ✓ |
| Agilent Technologies | ✓ | ✓ | − | − | ◐ | ◐ |
| Illumina Inc. | − | − | − | − | ◐ | − |
| Genzyme Corporation (Sanofi) | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific85
2Abbott Laboratories82
3PerkinElmer72
4Bio-Rad Laboratories71
5Agilent Technologies65
6F. Hoffmann-La Roche AG60
7Illumina Inc.51
8Genzyme Corporation (Sanofi)50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificAbbott Laboratories
Challenger2
Strong scale, closing on the leaders.
Bio-Rad LaboratoriesPerkinElmer
Contender2
Focused players with pockets of strength.
F. Hoffmann-La Roche AGAgilent Technologies
Niche2
Specialists in a single segment or region.
Illumina Inc.Genzyme Corporation (Sanofi)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Inherited Metabolic Disorders Testing Market — a $338M beachhead inside a $5.02B market.
Beachhead (SOM)$338Mobtainable near-term
Serviceable (SAM)$2.03Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Enzymatic Assays
Best fit — highest urgency & budget in Test Type.
Economic buyer77 fit
Molecular Genetic Testing
Strong fit — clear ROI and a fast path to value.
End user68 fit
Newborn Screening
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disorder Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Inherited Metabolic Disorders Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified26%
Evaluation14%
Closed-won6%
$15.4KCAC
$63KLTV
4.1:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Inherited Metabolic Disorders Testing Market is a resilient opportunity — $2.85B by 2033, compounding at 4.6%.
TAM · 2025$1.99Btoday
TAM · 2033$2.85Bforecast
CAGR4.6%2027–2033
Cumulative$21.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.85BTotal addressable market
SAM$1.10BServiceable available market
SOM$242MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.6% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.85BLarge & growingTAM by 2033 at 4.6% CAGR
$1.10BServiceable nowreachable with today’s model
$242MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.22BBear3.0% CAGR
$2.85BBase4.6% CAGR
$3.65BBull6.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disorder Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Inherited Metabolic Disorders Testing Market — a $8.86B market by 2033. Plan: grow share from 8.6% to 15.0%.
Market size · 2033$8.86Btotal addressable
Market CAGR9.7%2027–2033
Target share15.0%from 8.6% today
Revenue ambition$1.33Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.6% | 15.0% | At risk |
| Revenue | $735M | $1.33B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 28.8% | 40.0% | Behind |
| Customer retention | 87.2% | 95.4% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disorder Type capability
A defensible second engine — invest in Disorder Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disorder Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $192M capacity & capability investment
- Greenlight bolt-on M&A in Disorder Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Inherited Metabolic Disorders Testing Market conversation — a $5.78B market you can size, segment and defend in minutes.
Market size · 2033$5.78Btotal opportunity
Growth4.0%CAGR to 2033
Addressable buyers997+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificAbbott LaboratoriesBio-Rad LaboratoriesPerkinElmerF. Hoffmann-La Roche AGAgilent TechnologiesIllumina Inc.Genzyme Corporation (Sanofi)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Inherited Metabolic Disorders Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Inherited Metabolic Disorders Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Inherited Orphan Blood Disorders Therapeutics Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportInherited Retinal Disease Treatment Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportIn-Home Pet Euthanasia Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportIn-house Potting Soil Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportIn-house Sewer Pipes Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportInida Low Temperature Co-Fired Ceramic (Ltcc) Market
Inida Low Temperature Co-Fired Ceramic (Ltcc) Market is valued at USD 32 Million in 2025 and is…
$32M market · 2025 base year
View reportInida Nylon Resins Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportInitial Effect Plate Filter Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportInjectable Anti-Cancer Drug Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportInjectable Anti-Wrinkle Treatments Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportInjectable Bone Graft Substitutes Market
Market size, share, segmentation and regional forecast.
$815M market · 2025 base year
View reportInjectable Epoxy Anchoring Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.